Oncorus, Inc. (ONCR)


+0.01 (+0.00%)
Symbol ONCR
Price $0.021
Beta 2.181
Volume Avg. 0.02M
Market Cap 0.548M
Shares () -
52 Week Range 0.021-0.5269
1y Target Est -
DCF Unlevered ONCR DCF ->
DCF Levered ONCR LDCF ->
ROE -130.61% Strong Sell
ROA -68.08% Strong Sell
Operating Margin -
Debt / Equity 222.52% Strong Buy
P/E -0.01 Neutral
P/B 0.02 Neutral


Consensus EPS

Upgrades & Downgrades

Latest ONCR news

Mr. Craig R. Jalbert CIRA
NASDAQ Global Market

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.